Swiss National Bank
PHAT icon

Swiss National Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Swiss National Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
98,800
+6,200
+7% +$70.7K ﹤0.01% 2194
2026
Q1 		$1.03M Buy
92,600
+8,600
+10% +$109K ﹤0.01% 2147
2025
Q4 		$1.39M Buy
+84,000
New +$1.2M ﹤0.01% 2028
2025
Q2 		– Sell
-73,300
Closed -$460K – 2387
2025
Q1 		$460K Hold
73,300
– – ﹤0.01% 2354
2024
Q4 		$595K Hold
73,300
– – ﹤0.01% 2371
2024
Q3 		$1.33M Buy
73,300
+17,300
+31% +$242K ﹤0.01% 2087
2024
Q2 		$577K Hold
56,000
– – ﹤0.01% 2385
2024
Q1 		$595K Hold
56,000
– – ﹤0.01% 2415
2023
Q4 		$511K Sell
56,000
-4,200
-7% -$36.2K ﹤0.01% 2470
2023
Q3 		$624K Sell
60,200
-11,300
-16% -$155K ﹤0.01% 2453
2023
Q2 		$1.02M Buy
71,500
+31,100
+77% +$359K ﹤0.01% 2280
2023
Q1 		$288K Sell
40,400
-1,100
-3% -$9.66K ﹤0.01% 2612
2022
Q4 		$466K Hold
41,500
– – ﹤0.01% 2586
2022
Q3 		$460K Hold
41,500
– – ﹤0.01% 2598
2022
Q2 		$350K Buy
41,500
+8,100
+24% +$83.3K ﹤0.01% 2689
2022
Q1 		$455K Buy
33,400
+2,400
+8% +$38.8K ﹤0.01% 2615
2021
Q4 		$610K Hold
31,000
– – ﹤0.01% 2627
2021
Q3 		$995K Hold
31,000
– – ﹤0.01% 2441
2021
Q2 		$1.05M Buy
31,000
+14,400
+87% +$516K ﹤0.01% 2463
2021
Q1 		$623K Buy
16,600
+500
+3% +$20.9K ﹤0.01% 2438
2020
Q4 		$535K Hold
16,100
– – ﹤0.01% 2451
2020
Q3 		$590K Hold
16,100
– – ﹤0.01% 2325
2020
Q2 		$530K Buy
+16,100
New +$619K ﹤0.01% 2370

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Swiss National Bank's PHAT Position: Q2 2026 in Review

Swiss National Bank increased its Phathom Pharmaceuticals (PHAT) stake by 6.7% in Q2 2026, buying an estimated $70.7K and bringing the position to 98,800 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2194.

Swiss National Bank first reported a position in PHAT in Q2 2020 and has held it in 23 quarters since. The position peaked at $1.39M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Swiss National Bank held 98,800 shares of Phathom Pharmaceuticals worth $1.07M as of Q2 2026.
  • Swiss National Bank bought 6,200 Phathom Pharmaceuticals shares in Q2 2026, an estimated $70.7K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #2194 holding.
  • Swiss National Bank first reported a position in Phathom Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Swiss National Bank's Phathom Pharmaceuticals position peaked at $1.39M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.